Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Swedish Childhood Cancer Foundation | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Oral mucositis (OM) is a common adverse effect of chemotherapy, radiotherapy and conditioning regimens before Hematopoietic Stem Cell Transplantation (HSCT). The aim of this study is to effectiveness of cryotherapy as a prophylactic treatment in children undergoing HSCT.
There is a complex pathobiology behind OM; chemo and radiotherapy affects the mucosa and submucosa causing DNA-strand brakes and generation of reactive oxygen species (ROS). This initiates a cascade of events, among others activation of transcription factors, up-regulation of pro-inflammatory cytokines, and activation of macrophages and proteases leading to tissue injury causing symptoms such as erythema, edema, ulceration, taste perception alterations, and mouth dryness. OM often causes local and systemic infections, fatigue, pain, and difficulties in basal functions such as swallowing (and hence drinking and eating) and talking and reduces patients' psychological well-being. Nearly 90 % of pediatric patients undergoing HSCT are afflicted with OM. In pediatric patients mucositis is reported as one of the most painful and debilitating side effects during cancer treatment.Beyond a significant suffering for the patient it is hence associated with higher costs for health care and increased mortality.
The current scientific situation regarding prevention and treatment of OM has been summarized in Cochrane reports showing limited data on adults and practically missing data on children and adolescents. Concluding guidelines from these reports emphasize the need for well conducted randomized controlled trials (RCT's) to evaluate and refine treatments in order to establish evidence based interventions.
The use of cryotherapy to prevent oral mucositis in patients who are receiving high-dose chemotherapy as a conditioning agent prior to HSCT continue to show evidence in the adult population.
The aim of this study is to compare treatment with cryotherapy (Arm 1)with a standard oral care protocal (Arm 2)
ARM 1 Children are instructed to use chew on ice-chips, ingest ice-cream or ice-water during infusion of chemotherapy as part of the conditioning treatment prior to HSCT. Melted ice should be replaced by new as soon as possible. Children receiving a 24-hour infusion are instructed to use cryotherapy for one hour 4 times a day.
ARM 2 Standard care for prevention and management of oral mucositis
Primary outcome
Secondary outcomes
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cryotherapy | Experimental | Cryotherapy during conditioning treatment with chemotherapy prior to HSCT |
|
| Control | No Intervention | Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cryotherapy | Other | Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mucositis grade - WHO Oral Toxicity Scale | WHO-Oral toxicity scale Grade 0 - No mucositis Grade 1 - Erythema and/or soreness Grade 2 - Erythema and/or ulcers. Can eat solid food. Grade 3 - Erythema and/or Ulcers. No solid food but can ingest liquids. Grade 4 - Oral alimentation not possible. | Daily until engraftment, an expected average of 20 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Mucositis grade - Children´s International Mucositis Evaluation Scale (ChiMES) | Daily evaluation by child and parent. | Daily until engraftment, an expected average of 20 days. |
| Pain - Childrens Hospital Eastern Ontario Pain Scale (CHEOPS) |
| Measure | Description | Time Frame |
|---|---|---|
| Opioid consumption | Days with, and dose of morphine-equivalent opioids | During hospitalization in connection with HSCT, an expected average of 25 days |
| Duration of parenteral nutrition | Days with Total Parenteral Nutrition |
Inclusion Criteria:
Age between 4-18 Undergoing Hematopoietic Stem Cell Transplantation in Sweden sufficient knowledge in swedish to understand the protocols -
Exclusion Criteria:
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gustaf Ljungman, MD, PhD | Uppsala University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pediatric Oncology Department, Queen Silvia Childrens´ Hospital | Gothenburg | SE-41685 | Sweden | |||
| Departent of Pediatric Oncology, Lund University Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31993753 | Derived | Kamsvag T, Svanberg A, Legert KG, Arvidson J, von Essen L, Mellgren K, Toporski J, Winiarski J, Ljungman G. Prevention of oral mucositis with cryotherapy in children undergoing hematopoietic stem cell transplantations-a feasibility study and randomized controlled trial. Support Care Cancer. 2020 Oct;28(10):4869-4879. doi: 10.1007/s00520-019-05258-2. Epub 2020 Jan 28. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013280 | Stomatitis |
| D010146 | Pain |
| D007239 | Infections |
| ID | Term |
|---|---|
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D017679 | Cryotherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Daily assessment by nurse
| Daily until Engraftment an expected average of 20 days. |
| Mouth Pain | Mouth Pain measured with Numerical Rating scale(NRS)for children >7 years and parents and Facial Pain Scale(FPS) for children < 7 years | Daily until Engraftment an expected average of 20 days |
| Emotional and Psychological status | Beck youth inventories for depression and anxiety | Daily until engraftment, an expected average of 20 days. |
| During hospitalization in connection with HSCT, an expected average of 25 days |
| Weight Loss | Weight Loss in kilograms from admission to date of engraftment | During hospitalization in connection with HSCT, an expected average of 25 days |
| Duration of Antibiotic treatment | Days with antibiotics | During hospitalization in connection with HSCT, an expected average of 25 days |
| Duration of febrile neutropenia | Days with fever >38.0 degrees | Until engraftment, an expected average of 20 days |
| Duration of Hospitalisation | Counted from day 0 until discharge either home or to region hospital. | During hospitalization in connection with HSCT, an expected average of 25 days |
| C reactive protein | Level of p-CRP in comparison to grade of mucositis | During hospitalization in connection with HSCT, an expected average of 25 days |
| S-Albumin | In correlation to grade of Oral Mucositis | During hospitalization in connection with HSCT, an expected average of 25 days |
| Lund |
| SE-22185 |
| Sweden |
| Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Hudding | Stockholm | SE-14186 | Sweden |
| Department of pediatrics B78, Karolinska University Hospital | Stockholm | Se-14186 | Sweden |
| Department of Hematology, Uppsala University Hospital | Uppsala | SE-75185 | Sweden |
| D013568 |
| Pathological Conditions, Signs and Symptoms |